Observational studyFrontiers in endocrinology2025
Optical coherence tomography and electroretinography in pituitary macroadenomas: a 12-month analysis by age and tumor type.
Observational study in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate longitudinal changes in optical coherence tomography (OCT) and electroretinography (ERG) parameters over 12 months in patients with pituitary macroadenomas, and to assess variation according to age and tumor type. Methods: This prospective observational study included 36 patients (72 eyes) with newly diagnosed pituitary macroadenomas. Patients were divided into a treatment group (n=23; including 9 prolactinomas (PRL), and 14 non-functioning adenomas [NFPAs]) and an observation group (n=13; all NFPAs). Both groups were further stratified by age (<60 vs. ≥60 years). Retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness was measured by OCT, while functional assessment included photopic negative response (PhNR) amplitude and W-ratio from full-field ERG. Measurements were performed at baseline and 12 months. Comparative and correlation analyses evaluated longitudinal, age-, and tumor-related differences. Results: Mean age did not differ between groups (treatment: 57.4 ± 13.0 years; observation: 54.9 ± 17.2). GCIPL thickness showed no consistent group differences, except temporal thinning in observation patients ≥60 years. RNFL thinning was significant in treated patients ≥60 years (average and inferior/temporal quadrants) and in younger treated patients (<60 years) in the superior and nasal quadrants. Observation patients <60 years showed RNFL loss in average and superior values, whereas no significant RNFL changes occurred in those ≥60 years. PhNR amplitude decreased in treated patients ≥60 years, while W-ratio increased in both treated subgroups and in younger observation patients. Strong structure-function correlations were observed in treated patients ≥60 years, particularly between GCIPL average and PhNR amplitude (R=-0.51) and RNFL superior and PhNR amplitude (R=-0.63). Conclusions: Structural and functional retinal parameters (GCIPL, RNFL, PhNR) may provide supportive information for monitoring visual pathway involvement in pituitary macroadenomas. Differences between PRL and NFPAs were more evident in treated NFPA patients <60 years, suggesting tumor type and age may influence biomarker sensitivity. The absence of such differences in older patients may reflect biological homogeneity or reduced responsiveness of retinal structures. Age should be considered a potential modifier when interpreting OCT and ERG findings across clinical phenotypes of pituitary macroadenomas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.